Literature DB >> 1168168

Specific effect of neuraminidase on blastogenic response of sensitized lymphocytes.

T Han.   

Abstract

The blastogenic response of sensitized lymphocytes from guinea-pigs to 'de novo' antigens (KLH, HCH and PPD) was ehhanced by BCN treatment in twenty-one of twenty-three instances. In contrast, no effect of VCN on nonsensitized guinea-pig lymphocyte response to these antigens, or to mumps antigen, was noted in any of thirty-four instances, These findings indicate that the enhancement effect of VCN is specific for sensitized lymphocytes. Heating VCN at 100 degrees for 10 minutes completely abolished the enhancement effect on the lymphocyte response. VCN treatment did not change the kinetics of antigen-induced blastogenesis. The increased lymphocyte response could probably be related to unmasking of the antigen receptor sites of the cells, resulting in increased antigen uptake, following the VCN treatment.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1168168      PMCID: PMC1445817     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  10 in total

1.  Effect of neuraminidase on the stimulatory capacity of cells in human mixed lymphocyte cultures.

Authors:  G Lundgren; R L Simmons
Journal:  Clin Exp Immunol       Date:  1971-12       Impact factor: 4.330

2.  Enhancement of delayed skin hypersensitivity by neuraminidase in cancer patients.

Authors:  T Han
Journal:  Clin Exp Immunol       Date:  1974-09       Impact factor: 4.330

Review 3.  Biochemical and biophysical properties of cell membranes.

Authors:  E J Ambrose
Journal:  Proc Can Cancer Conf       Date:  1967

4.  Enhancement of in vitro lymphocyte response by neuraminidase.

Authors:  T Han
Journal:  Clin Exp Immunol       Date:  1973-01       Impact factor: 4.330

5.  Simplified whole blood method for evaluating in vitro lymphocyte reactivity of laboratory animals.

Authors:  T Han; J Pauly
Journal:  Clin Exp Immunol       Date:  1972-05       Impact factor: 4.330

6.  Increase of leukemia L1210 immunogenicity by Vibrio cholerae neuraminidase treatment.

Authors:  J G Bekesi; G St-Arneault; J F Holland
Journal:  Cancer Res       Date:  1971-12       Impact factor: 12.701

7.  The mechanism of phytohemagglutinin (PHA) action. 3. Stimulation of lymphocytes by allogeneic lymphocytes and phytohemagglutinin.

Authors:  K Lindahl-Kiessling; R D Peterson
Journal:  Exp Cell Res       Date:  1969-04       Impact factor: 3.905

8.  An alteration in tumor histocompatibility induced by neuraminidase.

Authors:  B H Sanford
Journal:  Transplantation       Date:  1967-09-05       Impact factor: 4.939

9.  Immunotherapy of cancer: immunospecific rejection of tumors in recipients of neuraminidase-treated tumor cells plus BCG.

Authors:  R L Simmons; A Rios
Journal:  Science       Date:  1971-11-05       Impact factor: 47.728

10.  Tumour specific immunogenicity of methylcholanthrene-induced sarcoma cells after incubation in neuraminidase.

Authors:  G A Currie; K D Bagshawe
Journal:  Br J Cancer       Date:  1969-03       Impact factor: 7.640

  10 in total
  4 in total

1.  Adjuvant immunotherapy with BCG in squamous-cell bronchial carcinoma. Immune-reactivity in relation to immunostimulation (preliminary results in a controlled trial).

Authors:  H M Jansen; T H The; G C de Gast; M T Esselink; A M van der Wal; N G Orie
Journal:  Thorax       Date:  1978-08       Impact factor: 9.139

2.  Friend virus-induced immunodepression: effect of neuraminidase treatment on Thy-1.2 antigen expression and cytotoxic potential of splenocytes from virus-infected mice.

Authors:  A A Mascio; W S Ceglowski
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

3.  Enhancement of T-cell response to PWM by neuraminidase-treated non-T cells.

Authors:  T Sakano
Journal:  Immunology       Date:  1980-02       Impact factor: 7.397

4.  Neuraminidase and tumor immunotherapy.

Authors:  H H Sedlacek; F R Seiler; H G Schwick
Journal:  Klin Wochenschr       Date:  1977-03-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.